SOAM
GILD icon

SBI Okasan Asset Management’s Gilead Sciences GILD Stock Holding History

SBI Okasan Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Sell
13,000
-1,590
-11% -$209K 0.05% 72
2026
Q1 		$1.99M Buy
14,590
+1,379
+10% +$193K 0.08% 42
2025
Q4 		$1.65M Buy
+13,211
New +$1.61M 0.09% 58

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Okasan Asset Management's GILD Position: Q2 2026 in Review

SBI Okasan Asset Management reduced its Gilead Sciences (GILD) stake by 11% in Q2 2026, selling an estimated $209K and leaving 13,000 shares worth $1.64M. The position accounts for 0.05% of the portfolio, ranked #72.

SBI Okasan Asset Management first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.99M in Q1 2026. 2,274 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • SBI Okasan Asset Management held 13,000 shares of Gilead Sciences worth $1.64M as of Q2 2026.
  • SBI Okasan Asset Management sold 1,590 Gilead Sciences shares in Q2 2026, an estimated $209K.
  • Gilead Sciences made up 0.05% of SBI Okasan Asset Management's portfolio in Q2 2026, its #72 holding.
  • SBI Okasan Asset Management first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • SBI Okasan Asset Management's Gilead Sciences position peaked at $1.99M in Q1 2026.
  • 2,274 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.